459 related articles for article (PubMed ID: 24508459)
21. Prostate cancer-associated SPOP mutations lead to genomic instability through disruption of the SPOP-HIPK2 axis.
Jin X; Qing S; Li Q; Zhuang H; Shen L; Li J; Qi H; Lin T; Lin Z; Wang J; Cao X; Yang J; Ma Q; Cong L; Xi Y; Fang S; Meng X; Gong Z; Ye M; Wang S; Wang C; Gao K
Nucleic Acids Res; 2021 Jul; 49(12):6788-6803. PubMed ID: 34133717
[TBL] [Abstract][Full Text] [Related]
22. ERK1/2 inhibits Cullin 3/SPOP-mediated PrLZ ubiquitination and degradation to modulate prostate cancer progression.
Fan Y; Hou T; Dan W; Zhu Y; Liu B; Wei Y; Wang Z; Gao Y; Zeng J; Li L
Cell Death Differ; 2022 Aug; 29(8):1611-1624. PubMed ID: 35194188
[TBL] [Abstract][Full Text] [Related]
23. SPOP-mutant prostate cancer: Translating fundamental biology into patient care.
Bernasocchi T; Theurillat JP
Cancer Lett; 2022 Mar; 529():11-18. PubMed ID: 34974131
[TBL] [Abstract][Full Text] [Related]
24. Tumor suppressor SPOP ubiquitinates and degrades EglN2 to compromise growth of prostate cancer cells.
Zhang L; Peng S; Dai X; Gan W; Nie X; Wei W; Hu G; Guo J
Cancer Lett; 2017 Apr; 390():11-20. PubMed ID: 28089830
[TBL] [Abstract][Full Text] [Related]
25. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.
Watson PA; Chen YF; Balbas MD; Wongvipat J; Socci ND; Viale A; Kim K; Sawyers CL
Proc Natl Acad Sci U S A; 2010 Sep; 107(39):16759-65. PubMed ID: 20823238
[TBL] [Abstract][Full Text] [Related]
26. Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy.
Liao Y; Liu Y; Xia X; Shao Z; Huang C; He J; Jiang L; Tang D; Liu J; Huang H
Theranostics; 2020; 10(8):3366-3381. PubMed ID: 32206096
[No Abstract] [Full Text] [Related]
27. Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation.
An J; Ren S; Murphy SJ; Dalangood S; Chang C; Pang X; Cui Y; Wang L; Pan Y; Zhang X; Zhu Y; Wang C; Halling GC; Cheng L; Sukov WR; Karnes RJ; Vasmatzis G; Zhang Q; Zhang J; Cheville JC; Yan J; Sun Y; Huang H
Mol Cell; 2015 Sep; 59(6):904-16. PubMed ID: 26344096
[TBL] [Abstract][Full Text] [Related]
28. Structural Insights into BET Client Recognition of Endometrial and Prostate Cancer-Associated SPOP Mutants.
Ostertag MS; Hutwelker W; Plettenburg O; Sattler M; Popowicz GM
J Mol Biol; 2019 May; 431(11):2213-2221. PubMed ID: 31026449
[TBL] [Abstract][Full Text] [Related]
29. SPOP-mediated ubiquitination and degradation of PDK1 suppresses AKT kinase activity and oncogenic functions.
Jiang Q; Zheng N; Bu L; Zhang X; Zhang X; Wu Y; Su Y; Wang L; Zhang X; Ren S; Dai X; Wu D; Xie W; Wei W; Zhu Y; Guo J
Mol Cancer; 2021 Aug; 20(1):100. PubMed ID: 34353330
[TBL] [Abstract][Full Text] [Related]
30. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.
Janouskova H; El Tekle G; Bellini E; Udeshi ND; Rinaldi A; Ulbricht A; Bernasocchi T; Civenni G; Losa M; Svinkina T; Bielski CM; Kryukov GV; Cascione L; Napoli S; Enchev RI; Mutch DG; Carney ME; Berchuck A; Winterhoff BJN; Broaddus RR; Schraml P; Moch H; Bertoni F; Catapano CV; Peter M; Carr SA; Garraway LA; Wild PJ; Theurillat JP
Nat Med; 2017 Sep; 23(9):1046-1054. PubMed ID: 28805821
[TBL] [Abstract][Full Text] [Related]
31. GLI3 Is Stabilized by SPOP Mutations and Promotes Castration Resistance via Functional Cooperation with Androgen Receptor in Prostate Cancer.
Burleson M; Deng JJ; Qin T; Duong TM; Yan Y; Gu X; Das D; Easley A; Liss MA; Yew PR; Bedolla R; Kumar AP; Huang TH; Zou Y; Chen Y; Chen CL; Huang H; Sun LZ; Boyer TG
Mol Cancer Res; 2022 Jan; 20(1):62-76. PubMed ID: 34610962
[TBL] [Abstract][Full Text] [Related]
32. TBLR1 as an androgen receptor (AR) coactivator selectively activates AR target genes to inhibit prostate cancer growth.
Daniels G; Li Y; Gellert LL; Zhou A; Melamed J; Wu X; Zhang X; Zhang D; Meruelo D; Logan SK; Basch R; Lee P
Endocr Relat Cancer; 2014 Feb; 21(1):127-42. PubMed ID: 24243687
[TBL] [Abstract][Full Text] [Related]
33. SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression.
Gan W; Dai X; Lunardi A; Li Z; Inuzuka H; Liu P; Varmeh S; Zhang J; Cheng L; Sun Y; Asara JM; Beck AH; Huang J; Pandolfi PP; Wei W
Mol Cell; 2015 Sep; 59(6):917-30. PubMed ID: 26344095
[TBL] [Abstract][Full Text] [Related]
34. Phosphorylation-dependent regulation of SPOP by LIMK2 promotes castration-resistant prostate cancer.
Nikhil K; Haymour HS; Kamra M; Shah K
Br J Cancer; 2021 Mar; 124(5):995-1008. PubMed ID: 33311589
[TBL] [Abstract][Full Text] [Related]
35. SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression.
Zhang J; Chen M; Zhu Y; Dai X; Dang F; Ren J; Ren S; Shulga YV; Beca F; Gan W; Wu F; Lin YM; Zhou X; DeCaprio JA; Beck AH; Lu KP; Huang J; Zhao C; Sun Y; Gao X; Pandolfi PP; Wei W
Dev Cell; 2019 Feb; 48(3):329-344.e5. PubMed ID: 30595538
[TBL] [Abstract][Full Text] [Related]
36. Snail promotes prostate cancer migration by facilitating SPOP ubiquitination and degradation.
Lv W; Huan M; Yang W; Gao Y; Wang K; Xu S; Zhang M; Ma J; Wang X; Chen Y; Li L
Biochem Biophys Res Commun; 2020 Aug; 529(3):799-804. PubMed ID: 32736710
[TBL] [Abstract][Full Text] [Related]
37. The Mutational and Transcriptional Landscapes of Speckle-Type POZ Protein (SPOP) and Androgen Receptor (AR) in a Single-Center pT3 Prostatectomy Cohort.
Eryilmaz IE; Vuruskan BA; Kaygisiz O; Cecener G; Egeli U; Vuruskan H
J Environ Pathol Toxicol Oncol; 2024; 43(1):15-29. PubMed ID: 37824367
[TBL] [Abstract][Full Text] [Related]
38. SPOP is essential for DNA-protein cross-link repair in prostate cancer cells: SPOP-dependent removal of topoisomerase 2A from the topoisomerase 2A-DNA cleavage complex.
Watanabe R; Maekawa M; Hieda M; Taguchi T; Miura N; Kikugawa T; Saika T; Higashiyama S
Mol Biol Cell; 2020 Mar; 31(6):478-490. PubMed ID: 31967940
[TBL] [Abstract][Full Text] [Related]
39. SPOP mutations promote p62/SQSTM1-dependent autophagy and Nrf2 activation in prostate cancer.
Shi Q; Jin X; Zhang P; Li Q; Lv Z; Ding Y; He H; Wang Y; He Y; Zhao X; Zhao SM; Li Y; Gao K; Wang C
Cell Death Differ; 2022 Jun; 29(6):1228-1239. PubMed ID: 34987184
[TBL] [Abstract][Full Text] [Related]
40. Speckle-type POZ protein mutations interrupt tumor suppressor function of speckle-type POZ protein in prostate cancer by affecting androgen receptor degradation.
Lai J; Batra J
Asian J Androl; 2014; 16(5):659-60. PubMed ID: 24969063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
